Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl

Catherine A. Vaughan, Shilpa Singh, Brad Windle, William Andrew Yeudall, Rebecca Frum, Steven R. Grossman, Swati P. Deb, Sumitra Deb

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

p53 mutations are present in up to 70% of lung cancer. Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 or no p53. Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis. In our study of this aggressive phenotype, we have investigated the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and -D281G. Knockdown of endogenous mutant p53 levels in human lung cancer cells H1048 (p53-R273C) and H1437 (p53-R267P) led to a reduction in the level of Axl as well. This effect on Axl expression is refractory to the mutations at positions 22 and 23 of p53, suggesting that p53's transactivation domain may not play a critical role in the up-regulation of Axl gene expression. Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies demonstrated induced histone acetylation on the Axl promoter region by mutant p53. Direct mutant p53 nucleation on the Axl promoter was demonstrated by ChIP assays using antibodies against p53. The Axl promoter has a p53/p63 binding site, which however is not required for mutant p53-mediated transactivation. Knockdown of Axl by Axl-specific RNAi caused a reduction of gain-of-function (GOF) activities, reducing the cell growth rate and motility rate in lung cancer cells expressing mutant p53. This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.

Original languageEnglish (US)
Pages (from-to)491-502
Number of pages12
JournalGenes and Cancer
Volume3
Issue number7-8
DOIs
StatePublished - Dec 1 2012

Fingerprint

Receptor Protein-Tyrosine Kinases
Lung Neoplasms
Up-Regulation
Chromatin Immunoprecipitation
Histones
Mutation
Transcriptional Activation
Antibodies
Gene Expression Regulation
Acetylation
Growth
RNA Interference
Genetic Promoter Regions
Neoplasms
Carcinogenesis
Binding Sites
RNA
Phenotype
Gene Expression
Cell Line

Keywords

  • Axl
  • lung
  • mutant
  • p53

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl. / Vaughan, Catherine A.; Singh, Shilpa; Windle, Brad; Yeudall, William Andrew; Frum, Rebecca; Grossman, Steven R.; Deb, Swati P.; Deb, Sumitra.

In: Genes and Cancer, Vol. 3, No. 7-8, 01.12.2012, p. 491-502.

Research output: Contribution to journalArticle

Vaughan, Catherine A. ; Singh, Shilpa ; Windle, Brad ; Yeudall, William Andrew ; Frum, Rebecca ; Grossman, Steven R. ; Deb, Swati P. ; Deb, Sumitra. / Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl. In: Genes and Cancer. 2012 ; Vol. 3, No. 7-8. pp. 491-502.
@article{b06f5333049b4b2b9842c36ff397a63b,
title = "Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl",
abstract = "p53 mutations are present in up to 70{\%} of lung cancer. Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 or no p53. Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis. In our study of this aggressive phenotype, we have investigated the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and -D281G. Knockdown of endogenous mutant p53 levels in human lung cancer cells H1048 (p53-R273C) and H1437 (p53-R267P) led to a reduction in the level of Axl as well. This effect on Axl expression is refractory to the mutations at positions 22 and 23 of p53, suggesting that p53's transactivation domain may not play a critical role in the up-regulation of Axl gene expression. Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies demonstrated induced histone acetylation on the Axl promoter region by mutant p53. Direct mutant p53 nucleation on the Axl promoter was demonstrated by ChIP assays using antibodies against p53. The Axl promoter has a p53/p63 binding site, which however is not required for mutant p53-mediated transactivation. Knockdown of Axl by Axl-specific RNAi caused a reduction of gain-of-function (GOF) activities, reducing the cell growth rate and motility rate in lung cancer cells expressing mutant p53. This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.",
keywords = "Axl, lung, mutant, p53",
author = "Vaughan, {Catherine A.} and Shilpa Singh and Brad Windle and Yeudall, {William Andrew} and Rebecca Frum and Grossman, {Steven R.} and Deb, {Swati P.} and Sumitra Deb",
year = "2012",
month = "12",
day = "1",
doi = "10.1177/1947601912462719",
language = "English (US)",
volume = "3",
pages = "491--502",
journal = "Genes and Cancer",
issn = "1947-6019",
publisher = "SAGE Publications Inc.",
number = "7-8",

}

TY - JOUR

T1 - Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl

AU - Vaughan, Catherine A.

AU - Singh, Shilpa

AU - Windle, Brad

AU - Yeudall, William Andrew

AU - Frum, Rebecca

AU - Grossman, Steven R.

AU - Deb, Swati P.

AU - Deb, Sumitra

PY - 2012/12/1

Y1 - 2012/12/1

N2 - p53 mutations are present in up to 70% of lung cancer. Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 or no p53. Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis. In our study of this aggressive phenotype, we have investigated the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and -D281G. Knockdown of endogenous mutant p53 levels in human lung cancer cells H1048 (p53-R273C) and H1437 (p53-R267P) led to a reduction in the level of Axl as well. This effect on Axl expression is refractory to the mutations at positions 22 and 23 of p53, suggesting that p53's transactivation domain may not play a critical role in the up-regulation of Axl gene expression. Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies demonstrated induced histone acetylation on the Axl promoter region by mutant p53. Direct mutant p53 nucleation on the Axl promoter was demonstrated by ChIP assays using antibodies against p53. The Axl promoter has a p53/p63 binding site, which however is not required for mutant p53-mediated transactivation. Knockdown of Axl by Axl-specific RNAi caused a reduction of gain-of-function (GOF) activities, reducing the cell growth rate and motility rate in lung cancer cells expressing mutant p53. This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.

AB - p53 mutations are present in up to 70% of lung cancer. Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 or no p53. Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis. In our study of this aggressive phenotype, we have investigated the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and -D281G. Knockdown of endogenous mutant p53 levels in human lung cancer cells H1048 (p53-R273C) and H1437 (p53-R267P) led to a reduction in the level of Axl as well. This effect on Axl expression is refractory to the mutations at positions 22 and 23 of p53, suggesting that p53's transactivation domain may not play a critical role in the up-regulation of Axl gene expression. Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies demonstrated induced histone acetylation on the Axl promoter region by mutant p53. Direct mutant p53 nucleation on the Axl promoter was demonstrated by ChIP assays using antibodies against p53. The Axl promoter has a p53/p63 binding site, which however is not required for mutant p53-mediated transactivation. Knockdown of Axl by Axl-specific RNAi caused a reduction of gain-of-function (GOF) activities, reducing the cell growth rate and motility rate in lung cancer cells expressing mutant p53. This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.

KW - Axl

KW - lung

KW - mutant

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=84875509079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875509079&partnerID=8YFLogxK

U2 - 10.1177/1947601912462719

DO - 10.1177/1947601912462719

M3 - Article

C2 - 23264849

AN - SCOPUS:84875509079

VL - 3

SP - 491

EP - 502

JO - Genes and Cancer

JF - Genes and Cancer

SN - 1947-6019

IS - 7-8

ER -